A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors

Summary

The purpose of this study is to evaluate the effectiveness and safety of relatlimab in combination with nivolumab in participants with advanced liver cancer who have never been treated with immuno-oncology therapy, after prior treatment with tyrosine kinase inhibitor therapy.

Timeline

Start

2021-02-04

Primary completion

2023-08-31

Completion

2025-11-19

Outcome

Missed primary endpoint

registry analysis (superiority test); Treatment A vs Treatment B; Strata adjusted difference in ORR -2.7 (95% CI -10.7 to 5.3) NCT04567615 ↗

Drugs

Indications